A special article in the December issue of Arthritis & Rheumatology summarizes the current understanding of the cardiac toxicity of HCQ and CQ.
Clinical Rheumatology Year in Review 2021
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
Extreme & Uncontrollable Circumstances Policy Will Apply to All MIPS-Eligible Clinicians 2021
The final rule, issued Nov. 2, finalizes many proposed policies, including a decreased conversion factor, billing for shared visits and teaching services, continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.
Passive Exposure to Smoking May Increase Rheumatoid Arthritis Risk
EULAR—Passive exposure to smoking during childhood or adulthood increases the risk of developing rheumatoid arthritis (RA), according to a large prospective cohort study of healthy French women presented during EULAR’s 2021 virtual European Congress of Rheumatology. Moreover, the association was mainly observed among women who had themselves never smoked.1 “In this study, we found an…
How to Find Space for Scholarship in Private Practice
A key question many graduating rheumatology fellows face each year is: Are you interested in pursuing a career in academic medicine or in private practice? Although the two tracks are not mutually exclusive, it is true that juggling the demands of scholarly work, medical education and a busy clinical workload is by no means easy….
The Clinical Value of Antiphospholipid Antibodies in Patients with COVID-19
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
Nonserious Infection Rates with Biologics Used to Treat RA
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.
RISE Registry Stakeholders Discuss Initiatives, Successes at Annual Strategy Summit
On Aug. 6, practice managers, clinicians and researchers gathered with ACR and RISE staff and volunteers to discuss the registry’s development and future.
Make an Impact: Join Our Community of Donors
The Rheumatology Research Foundation is proud to announce the launch of RheumBuilders, a new community of monthly donors, and the relaunch of its Legacy Society, a community of donors who have included the Foundation in their wills or estate plans. These initiatives are designed to deepen the Foundation’s commitment to rheumatology research and patient care,…
Will an App to Monitor Patient Outcomes Improve RA Disease Activity?
Lee et al. examined the use of a smartphone application to monitor longitudinal electronic patient-reported outcomes on satisfaction and disease activity in patients with RA.
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 123
- Next Page »